Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Post-menopausal Vasomotor Symptoms

In brief

In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients). The study drug works on a receptor in the brain and the intended purpose is for the study treatment of moderate to severe Vasomotor Symptoms (VMS) also referred to as hot flashes or flushes associated with menopause. Hot flashes are a change in your temperature that occurs due to changes in your hormones.

Key facts

Study ID
NCT05325775
Run by
Acer Therapeutics Inc.
People needed
49
Starts
2022-03-30
Expected to finish
2023-03-04
Last updated by the study team
2024-08-07

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.